Check out the full list of Castleman disease related projects that were presented at the 2018 American Society of Hematology Conference in San Diego, CA! To learn more about the CDCN's experience at the 2018 ASH conference, click here. To stay updated about CDCN and Castleman disease events at the 2019 ASH conference, click here

 1. Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease - Dustin Shilling, PhD, Jason R Ruth, PhD, Christopher Sheild Nabel, MD, PhD, Sheila K Pierson, MS, Mary Guilfoyle, MS, Craig Tendler, MD, Manjula P Reddy, MS, MSc, Michael Weinblatt, MD, Nancy Shadick, MD, MPH, Mark Bower, MD, Alessia Dalla Pria, MD, Yasufumi Masaki, MD, PhD, Philip Beineke, MS, Sofija Miljovska, MS, Laura Katz, MA, Sushila Shenoy, PhD, Ana B Oromendia, PhD, Jason Mezey, PhD, Jeff Wiser, MS, Jef Benbanaste, MBA, David Lee, MA, Alexander Fosså, MD, PhD, Frits van Rhee, MD, PhD and David C Fajgenbaum, MD, MBA, MSc

2. Pilot Study of Tocilizumab in Patients with HIV and Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease - Ramya Ramaswami, MBBS, MPH, Kathryn Lurain, MD, MPH, Anaida Widell, Mark N. Polizzotto, Priscila H. Goncalves, MD, Matthew Lindsley, Seth M. Steinberg, PhD, Denise Whitby, Thomas S. Uldrick, MD, MS and Robert Yarchoan, MD

3. Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients - Anna Wing, Wenzhao Meng, Ph.D., Gerald Wertheim, M.D., Ph.D, Dale Frank, M.D., Michele Paessler, D.O., Megan S. Lim, M.D., Ph.D., Eline T. Luning Prak, M.D., Ph.D., David C Fajgenbaum, MD, MBA, MSc and Vinodh Pillai, M.D., Ph.D

4. Oligoclonal Expansion of Cd8+ T Cells during Idiopathic Multicentric Castleman Disease Flares Suggests an Antigen Driven Process - Dustin Shilling, PhD, Jason E Stadanlick, PhD, Wenzhao Meng, Ph.D., Abhishek Rao, MS, Vera P Krymskaya, PhD, MBA, FCPP, Eline T. Luning Prak, M.D., Ph.D., Evgeniy B Eruslanov, PhD and David C Fajgenbaum, MD, MBA, MSc

5. Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center - Katie Stone, BS, Francisco Socola, MD, Amy Greenway1*, Samina Waheed, Kristen Carter, APRN, Diane Glendinning, APRN, Daisy Alapat, MD and Frits van Rhee, MD, PhD

6. Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization - Meera Mohan, MD, James C Meek, MD, Mary Elizabeth Meek, MD, Ralph Lynn Broadwater, MD, Katie Stone, BS, Amy Greenway, Daisy Alapat, MD and Frits van Rhee, MD, PhD

7. Single-Cell RNA-Sequencing of Peripheral Blood Mononuclear Cells Reveals Changes in Immune Cell Composition and Distinct Inflammatory Gene Expression Profiles during Idiopathic Multicentric Castleman Disease Flare - Ruth-Anne Langan, BA, Dustin Shilling, PhD, Michael Gonzalez, PhD, Charlly Kao, PhD, Hakon Hakonarson, MD, PhD, Taku Kambayashi, MD, PhD and David C Fajgenbaum, MD, MBA, MSc

8. A Prospective Phase II Study of Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Idiopathic Multicentric Castleman's Disease - Lu Zhang, MD, Ai-lin Zhao, MD, Jun Feng, MD, Xinxin Cao, MD, Yan Zhang, MD, Tienan Zhu, MD, Minghui Duan, MD, Daobin Zhou, MD and Jian Li, MD

9. Pi3k/Akt/Mtor Pathway Activity Is Increased in Lymph Node Tissue from Idiopathic Multicentric Castleman Disease Patients with Tafro Syndrome - Dustin Shilling, PhD, Dale M Kobrin, BA and David C Fajgenbaum, MD, MBA, MSc